CNS Pharmaceuticals (CNSP) News Today → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free CNSP Stock Alerts $0.20 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAnalyzing Arcutis Biotherapeutics (NASDAQ:ARQT) and CNS Pharmaceuticals (NASDAQ:CNSP)americanbankingnews.com - April 16 at 2:20 AMCNS Pharmaceuticals (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Updatetheglobeandmail.com - April 4 at 8:14 PMCNS Pharma Stock (NASDAQ:CNSP), Earnings Estimates, EPS, and Revenuebenzinga.com - April 3 at 6:16 PMCNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q4 2023investorplace.com - April 2 at 1:02 AMCNS Pharmaceuticals (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Boardtheglobeandmail.com - March 20 at 6:36 PMCns Pharmaceuticals Inc (CNSP)investing.com - February 9 at 1:08 AMCNS Pharmaceuticals Launches Public Offering for Trial Fundingmsn.com - February 3 at 10:27 AMCNS Pharmaceuticals (NASDAQ: CNSP) Releases Info on $4M Public Offering Pricingtheglobeandmail.com - January 30 at 3:06 PMCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offeringfinanznachrichten.de - January 29 at 11:02 PMCNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offeringfinance.yahoo.com - January 29 at 11:02 PMCNS Pharmaceuticals (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directorstheglobeandmail.com - January 19 at 5:34 PMCNS Pharmaceuticals, Inc.: Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directorsfinanznachrichten.de - January 18 at 10:14 AMBiotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directorsfinance.yahoo.com - January 18 at 10:14 AMCNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)finance.yahoo.com - January 17 at 1:28 PMCNSP CNS Pharmaceuticals, Inc.seekingalpha.com - January 6 at 7:55 PMCNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicinfinance.yahoo.com - December 18 at 9:50 AMCNS Pharmaceuticals Inc Ordinary Sharesmorningstar.com - December 14 at 2:57 PMCNS Pharmaceuticals files to sell 3.81M shares of common stockmsn.com - December 8 at 7:18 PMHow CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Curefinance.yahoo.com - December 6 at 9:30 AMCNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacyfinance.yahoo.com - November 22 at 9:30 AMCNS Pharmaceuticals files to sell 3.76M shares of common stock for holdersmsn.com - November 21 at 12:15 AMCNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidatefinance.yahoo.com - November 16 at 2:31 PMCNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year Endfinance.yahoo.com - November 15 at 8:50 AMCNS Pharmaceuticals Inc Ordinary Shares CNSPmorningstar.com - November 11 at 10:08 AMCNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conferencefinance.yahoo.com - October 19 at 9:17 AMCNS Pharma Stock (NASDAQ:CNSP) Dividends: History, Yield and Datesbenzinga.com - October 17 at 9:34 AMGlioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals’ Innovative Approach To Treatment Could Offer Hopefinance.yahoo.com - October 16 at 9:29 AMCNS Pharmaceuticals (NASDAQ: CNSP) Reports Rapid Pace of Enrollment in Berubicin Studytheglobeandmail.com - October 13 at 10:16 AMGlioblastoma Is the Most Aggressive Type Of Brain Cancer, With No Cure – CNS Pharmaceuticals' Innovative Approach To Treatment Could Offer Hopebenzinga.com - October 13 at 10:16 AMCNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Datefinance.yahoo.com - October 11 at 9:32 AMCNS Pharmaceuticals (NASDAQ: CNSP) Looking Forward to Interim Results for Potentially Pivotal GBM Studytheglobeandmail.com - September 8 at 4:04 PMCNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)finance.yahoo.com - September 7 at 9:42 AMCNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 5 at 5:01 PMCNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestonesfinance.yahoo.com - August 14 at 3:20 PMCNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapyfinance.yahoo.com - August 14 at 3:20 PMCNS Pharma's Lead Drug Candidate Crosses The Blood Brain Barrier - What Does That Mean? Watch the full show here!benzinga.com - August 8 at 10:35 AMCNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)finance.yahoo.com - August 3 at 8:31 AMCNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conferencefinance.yahoo.com - August 3 at 8:31 AMCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conferencefinanznachrichten.de - July 28 at 8:34 PMCNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conferencefinance.yahoo.com - July 27 at 9:55 AMCNSP - CNS Pharmaceuticals, Inc.finance.yahoo.com - July 21 at 7:55 PMCNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Seriesfinance.yahoo.com - July 5 at 10:22 AMCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vestfinanznachrichten.de - June 14 at 9:42 AMCNS Pharmaceuticals (NASDAQ:CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vestfinance.yahoo.com - June 14 at 9:42 AMCNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)finance.yahoo.com - May 25 at 10:27 AMMaxim Group Reaffirms Their Hold Rating on CNS Pharmaceuticals (CNSP)markets.businessinsider.com - May 16 at 8:42 PMBioMedNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2023 Results, Corporate Updatemarketwatch.com - May 16 at 10:42 AMCNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 15 at 1:52 PMBettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directorsfinance.yahoo.com - May 8 at 10:59 AMCNS Pharma investigation possible naked short sellingseekingalpha.com - May 4 at 7:53 AM Get CNS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. Email Address [Shocking] Elon Musk’s Plan To End Banks (Ad)Leaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. Click here now to get your copy. CNSP Media Mentions By Week CNSP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNSP News Sentiment▼0.000.48▲Average Medical News Sentiment CNSP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNSP Articles This Week▼11▲CNSP Articles Average Week Get CNS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CYCC News Today NTBL News Today SLRX News Today HSTO News Today CWBR News Today CMND News Today BPTH News Today LSDI News Today QLGN News Today CYTO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNSP) was last updated on 4/23/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlaceGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
